Announced Tue, 1 Sept, 2026 · 12:04 IST
Sakar Healthcare gets 14 oncology product approvals in EU, UK and Canada
SAKAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+14.2%1-day move
₹864.00
prior close
₹866.90
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+5.4+8.7+9.1+11.7+14.2+16.1+17.5+29.0+36.0+29.6+34.8+26.0——
Up moveDown movePending
AI summary
Sakar Healthcare has received 14 new oncology product approvals across EU, UK and Canada with 7 business partners. Approvals include 5 EMA site variations via Accord partner, 3 products from MHRA and EMA via UK and Germany partners, and 6 Marketing Authorizations. Products cover breast, lung, prostate, stomach, head and neck, colon, ovary, liver, kidney, thyroid, blood, bone-marrow and lymph cancers. Company expects boost to top-line sales in regulated markets.
Likely market impact
Expected to drive top-line sales growth in regulated EU, UK and Canada markets through licensed out and technology transfer deals.